cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Reata Pharmaceuticals Inc
13 own
12 watching
Current Price
$172.32
$0.15
(0.09%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
3,531.36M
52-Week High
52-Week High
172.36000
52-Week Low
52-Week Low
21.83000
Average Volume
Average Volume
0.75M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization3,531.36M
icon52-Week High172.36000
icon52-Week Low21.83000
iconAverage Volume0.75M
iconDividend Yield--
iconP/E Ratio--
What does the Reata Pharmaceuticals Inc do?
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with various serious or life-threatening diseases. The company focuses on drugs with novel mechanisms of action that modulate regulatory proteins called transcription factors. Its lead product candidates include bardoxolone methyl and RTA 408, which are members of a class of small molecules called antioxidant inflammation modulators. It is involved in LARIAT, a Phase II study of bardoxolone methyl for the treatment of pulmonary arterial hypertension and pulmonary hypertension due to interstitial lung disease. RTA 408 is in Phase II clinical development for the treatment of multiple diseases, including Friedreich's ataxia and mitochondrial myopathies. Reata Pharmaceuticals, Inc. was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. The company was founded in 2002 and is headquartered in Irving, Texas.
Read More
How much money does Reata Pharmaceuticals Inc make?
News & Events about Reata Pharmaceuticals Inc.
Globe Newswire
3 months ago
NEW YORK, June 19, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Reata Pharmaceuticals, Inc. (NASDAQ: RETA), DLocal Ltd. (NASDAQ: DLO), Comerica Incorporated (NYSE: CMA), and Advance Auto Parts, ...
Globe Newswire
3 months ago
NEW YORK, June 09, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Reata Pharmaceuticals, Inc. (NASDAQ: RETA), Comerica Incorporated (NYSE: CMA), and DZS Inc. (NASDAQ: DZSI). Our investigations ...
PR Newswire
3 months ago
RETA FRAUD ALERT: Jakubowitz Law is Investigating Reata Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws RETA FRAUD ALERT: Jakubowitz Law is Investigating Reata Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws PR...
Benzinga
5 months ago
read more...
Frequently Asked Questions
Frequently Asked Questions
What is Reata Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Reata Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Reata Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Reata Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Reata Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Reata Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Reata Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Reata Pharmaceuticals Inc?
plus_minus_icon
What percentage is Reata Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Reata Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$172.32
$0.15
(0.09%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Vaxcyte Inc
Vaxcyte Inc
$52.47
$0.28 (0.54 %)
Immunovant Inc
Immunovant Inc
$20.39
$-0.86 (-4.05 %)
Morphic Holding Inc
Morphic Holding Inc
$36.68
$-14.72 (-28.64 %)
Harmony Biosciences Holdings Inc
Harmony Biosciences Holdings Inc
$36.27
$0.55 (1.54 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Vaxcyte Inc
Vaxcyte Inc
$52.47
$0.28 (0.54 %)
Immunovant Inc
Immunovant Inc
$20.39
$-0.86 (-4.05 %)
Morphic Holding Inc
Morphic Holding Inc
$36.68
$-14.72 (-28.64 %)
Harmony Biosciences Holdings Inc
Harmony Biosciences Holdings Inc
$36.27
$0.55 (1.54 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00